Only some hopeful sEH inhibitor candidates are subjected now to clinical trials such as GSK2256294A in Phase-I and AR9281 in Phase-II against chronic obstructive pulmonary disease (COPD) and hypertension.513,514 However, the possibility of angiogenic effects when inhibiting sEH needs to be further evaluated. The gene discussed is EPHX2; the disease is Hypertension.